250
Participants
Start Date
February 28, 2007
Primary Completion Date
June 25, 2017
Study Completion Date
June 25, 2017
Rituximab
Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
Cyclophosphamide
Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
Doxorubicin
Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
Vincristine
Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
Prednisone 1
Prednisone 100 mg p.o. d. 1-5 q. 21 d.
Prednisone 2
Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
Podkarpacki Oncology Centre, Brzozów
Voivodeship Hospital, Oncology Ward, Elblag
Academic Clinical Centre, Hospital of Medical Academy, Clinic of Haematology and Transplantology, Gdansk
Silesian Medical University, Chair and Clinic of Haematology and Bone Marrow Transplantation, Katowice
Collegium Medicum Jagiellonian University, Clinic of Haematology, Krakow
Regional Oncology Centre, Ward of Proliferative Diseases, Lodz
Oncology Centre of Lublin Region, Lublin
Central Clinical Hospital, Ministry of Internal Matters and Administration; Clinic of Oncology, Haematology and Internal Diseases, Warsaw
Institute of Haematology and Transfusiology, Warsaw
M.Sklodowska-Curie Institute - Oncology Centre, Warsaw
Medical Academy in Wrocław; Chair and Clinic of Haematology, Blood Neoplasm and Bone Marrow Transplantation, Wroclaw
SP ZOZ Silesian Centre of Cellular Transplantation, Wroclaw
Polish Lymphoma Research Group
NETWORK